Cargando…

Toxic epidermal necrolysis after the administration of enfortumab vedotin for urinary bladder urothelial carcinoma

INTRODUCTION: Enfortumab vedotin is a novel drug for locally advanced or metastatic urothelial carcinoma, but it is associated with a high incidence of skin reactions (up to 47.0%). CASE PRESENTATION: A 71‐year‐old male was administered enfortumab vedotin for bladder cancer associated with lymph nod...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mimura, Yuji, Kobayashi, Aya, Utazu, Haruhiko, Matsumoto, Yuki, Mizusawa, Hiroya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9978062/ https://www.ncbi.nlm.nih.gov/pubmed/36874989 http://dx.doi.org/10.1002/iju5.12562

Ejemplares similares

Muscle invasive urinary bladder urothelial carcinoma presenting with secondary nephrotic symptoms
por: Mizusawa, Hiroya, et al.
Publicado: (2021)

A rare presentation of enfortumab vedotin–induced toxic epidermal necrolysis
por: Francis, Andrea, et al.
Publicado: (2020)

Enfortumab Vedotin in urothelial cancer
por: Alt, Marie, et al.
Publicado: (2020)

Enfortumab Vedotin-Induced Toxic Epidermal Necrolysis: A Rare Fatal Adverse Reaction
por: Bansal, Aditi, et al.
Publicado: (2022)

Enfortumab vedotin in metastatic urothelial carcinoma: the solution EVentually?
por: Maiorano, Brigida Anna, et al.
Publicado: (2023)

Administration of Enfortumab Vedotin after Immune-Checkpoint Inhibitor and the Prognosis in Japanese Metastatic Urothelial Carcinoma: A Large Database Study on Enfortumab Vedotin in Metastatic Urothelial Carcinoma
por: Kawahara, Takashi, et al.
Publicado: (2023)

Advancements in Therapy for Bladder Cancer: Enfortumab Vedotin
por: Hanna, Kirollos S.
Publicado: (2020)

Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date
por: Moussa, Mohamad, et al.
Publicado: (2021)

Cost-effectiveness of enfortumab vedotin in previously treated advanced urothelial carcinoma
por: Wu, Qiuji, et al.
Publicado: (2022)

Current and Emerging Treatments for Urothelial Carcinoma: A Focus on Enfortumab Vedotin
por: Shafique, Muhammad Ashir, et al.
Publicado: (2023)

Drug extravasation with Enfortumab vedotin
por: Grant, Christopher Ryan, et al.
Publicado: (2023)

Targeted Treatment of Locally Advanced and Metastatic Urothelial Cancer: Enfortumab Vedotin in Context
por: Hoffman-Censits, Jean, et al.
Publicado: (2022)

First Evidence of Activity of Enfortumab Vedotin on Brain Metastases in Urothelial Cancer Patients
por: Vulsteke, Christof, et al.
Publicado: (2023)

Flexural Exanthema From Enfortumab Vedotin
por: Keerty, Dinesh, et al.
Publicado: (2020)

Emerging Treatment Options for the Treatment of Metastatic Urothelial Cancer: Therapeutic Potential of Enfortumab Vedotin
por: Jain, Rohit K, et al.
Publicado: (2020)

Severe cutaneous drug toxicity following enfortumab vedotin treatment for metastatic urothelial carcinoma
por: Enescu, Christina D., et al.
Publicado: (2022)

FGFR2/3 genomic alterations and response to Enfortumab Vedotin in metastatic urothelial carcinoma
por: Adib, Elio, et al.
Publicado: (2021)

Case Report: Enfortumab Vedotin for Metastatic Urothelial Carcinoma: A Case Series on the Clinical and Histopathologic Spectrum of Adverse Cutaneous Reactions From Fatal Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis to Dermal Hypersensitivity Reaction
por: Viscuse, Paul V., et al.
Publicado: (2021)

THU354 Enfortumab Vedotin Induced Refractory Hyperglycemia
por: Hussein, Marwah, et al.
Publicado: (2023)

A phase I study of enfortumab vedotin in Japanese patients with locally advanced or metastatic urothelial carcinoma
por: Takahashi, Shunji, et al.
Publicado: (2019)

Complete Response to Enfortumab Vedotin in a Hemodialysis Patient with Metastatic Urothelial Carcinoma: A Case Report
por: Isoda, Bunpei, et al.
Publicado: (2023)

Diabetic Ketoacidosis and Acute Kidney Injury Associated With Enfortumab Vedotin for Urothelial Carcinoma: A Case Report
por: Atemnkeng, Francis, et al.
Publicado: (2023)

Response of Patients with Taxane-Refractory Advanced Urothelial Cancer to Enfortumab Vedotin, a Microtubule-Disrupting Agent
por: Miyake, Makito, et al.
Publicado: (2023)

Case Report: Safety and Efficacy of Enfortumab Vedotin in a Patient With Metastatic Urothelial Carcinoma Undergoing Peritoneal Dialysis
por: Collette, Kaylyn R., et al.
Publicado: (2022)

Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer
por: Jindal, Tanya, et al.
Publicado: (2023)

Effect of Enfortumab Vedotin Dose Adjustment on Efficacy in Metastatic Urothelial Carcinoma: A Retrospective Single-Center Experience 
por: Clennon, Anna, et al.
Publicado: (2023)

Enfortumab Vedotin in Metastatic Urothelial Carcinoma: Survival and Safety in a European Multicenter Real-world Patient Cohort
por: Zschäbitz, Stefanie, et al.
Publicado: (2023)

Enfortumab vedotin and pembrolizumab as monotherapies and combination treatment in locally advanced or metastatic urothelial carcinoma: A narrative review
por: Bantounou, Maria A., et al.
Publicado: (2023)

Patient with inguinal hernia containing the urinary bladder complicated by bladder stones
por: Inage, Kota, et al.
Publicado: (2019)

Two Cases of Exacerbation of Asthma during Treatment with Enfortumab Vedotin
por: Homma, Takamasa, et al.
Publicado: (2023)

Metastatic Penile Squamous Cell Carcinoma Responsive to Enfortumab Vedotin
por: Fahey, Catherine C., et al.
Publicado: (2023)

Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance
por: Klümper, Niklas, et al.
Publicado: (2023)

Bilateral Anterior Subcapsular Cataract Development Following Initiation of Enfortumab Vedotin
por: Thibodeau, Alexa, et al.
Publicado: (2021)

Cutaneous reactions with enfortumab vedotin: A case series and review of the literature
por: Dobry, Allison S., et al.
Publicado: (2021)

Enfortumab Vedotin–related Cutaneous Toxicity and Radiographic Response in Patients with Urothelial Cancer: A Single-center Experience and Review of the Literature
por: Vlachou, Evangelia, et al.
Publicado: (2023)

Metastatic bladder cancer forming a sigmoidorectal fistula after enfortumab vedotin therapy: a case report
por: Tamada, Shinji, et al.
Publicado: (2023)

Enfortumab Vedotin-induced Hyperglycemia and Ileal Conduit Reconstruction-induced Metabolic Acidosis
por: Sato, Takaaki, et al.
Publicado: (2023)

Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1/Programmed Death Ligand 1 Therapy
por: Rosenberg, Jonathan E., et al.
Publicado: (2019)

The Cost of Enfortumab Vedotin Wastage Due to Vial Size—A Real-World Analysis
por: Sarfaty, Michal, et al.
Publicado: (2021)

Characterization of cutaneous adverse events to enfortumab vedotin: A retrospective case-control study
por: Shahin, Ahmad, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_lrltk393ekaljuu7g8fljclf12